Conference
Abstract A50: Biomarker analysis of PTEN, targeted oncogenic mutations, and HPV in a phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor dacomitinib (D) (PF-299804) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).
Abstract
Abstract
Background: The pan-HER inhibitor D has demonstrated single-agent activity in a phase II trial of 69 patients (pts) with first-line RM SCCHN, reporting an objective response rate (ORR) of 12.7%, median progression-free survival (PFS) of 12.1 weeks (wks) and median overall survival (OS) of 35.9 wks (Siu et al. ASCO 2011). The identification of biomarkers predictive of sensitivity or resistance is of top priority to …
Authors
Siu LL; Allo G; Pond GR; Zhang T; Ho J; Hotte SJ; Laurie SA; Singh S; Winquist E; Chia SKL
Volume
10
Pagination
pp. a50-a50
Publisher
American Association for Cancer Research (AACR)
Publication Date
November 12, 2011
DOI
10.1158/1535-7163.targ-11-a50
Conference proceedings
Molecular Cancer Therapeutics
Issue
11_Supplement
ISSN
1535-7163